The level of pulmonary VEGF lowered significantly in the regorafenib group compared to the CLP group, supporting the results of Liu et al., who found that regorafenib reduced VEGF levels in human hepatocellular carcinoma cells and decreased the secretion and expression of angiogenesis-related proteins like TNF-α and IL-1β [20]. This evidence concerns the gene TNF and hepatocellular carcinoma.